(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 March 2010 (18.03.2010)

PCT

(10) International Publication Number
WO 2010/029374 A1

(51) International Patent Classification:
A61K 9/16 (2006.01) *A61K 47/14* (2006.01)
A61K 47/10 (2006.01) *A61K 9/00* (2006.01)

(21) International Application Number:
PCT/GB2009/051188

(22) International Filing Date:
14 September 2009 (14.09.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0816642.3 12 September 2008 (12.09.2008) GB
0820799.5 13 November 2008 (13.11.2008) GB

(71) Applicant *(for all designated States except US)*: **CRITICAL PHARMACEUTICALS LIMITED** [GB/GB]; BioCity Nottingham, Pennyfoot Street, Nottingham, Nottinghamshire NG1 1GF (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **ILLUM, Lisbeth** [DK/GB]; 19 Cavendish Crescent North, The Park, Nottingham, Nottinghamshire NG7 1BA (GB). **JORDAN, Faron, Michael** [GB/GB]; 6 Hawthorne Road, Bagworth, Coalville, Leicestershire LE67 1GU (GB). **LEWIS, Andrew, Lester** [GB/GB]; 3d Western Terrace, The Park, Nottingham, Nottinghamshire NG7 1AF (GB).

(74) Agents: **JONES, Stephen** et al.; Adamson Jones, BioCity Nottingham, Pennyfoot Street, Nottingham, Nottinghamshire NG1 1GF (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

WO 2010/029374 A1

(54) Title: IMPROVEMENTS IN THE ABSORPTION OF THERAPEUTIC AGENTS ACROSS MUCOSAL MEMBRANES OR THE SKIN

(57) Abstract: Absorption of a therapeutic agent across a mucosal membrane or the skin can be enhanced using an absorption enhancer comprising a hydroxy fatty acid ester of polyethylene glycol.